Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

PURPOSE: CLL cells treated with dasatinib in vitro undergo apoptosis via inhibition of Lyn kinase. Thus, in this study we tested the activity of dasatinib in patients with relapsed CLL. EXPERIMENTAL DESIGN: Patients were eligible for this phase 2 trial if they had documented CLL/SLL and had failed a...

詳細記述

保存先:
書誌詳細
主要な著者: Amrein, Philip C., Attar, Eyal C., Takvorian, Tak, Hochberg, Ephraim P., Ballen, Karen K., Leahy, Kathleen M., Fisher, David C., LaCasce, Ann S., Jacobsen, Eric D., Armand, Philippe, Hasserjian, Robert P., Werner, Lillian, Neuberg, Donna, Brown, Jennifer R.
フォーマット: Artigo
言語:Inglês
出版事項: 2011
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3108904/
https://ncbi.nlm.nih.gov/pubmed/21402714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2879
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料